✦ LIBER ✦

Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung cancer

✍ Scribed by Suresh S. Ramalingam; Judy Foster; William Gooding; Terry Evans; Matthew Sulecki; Chandra P. Belani

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 130 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24753

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I studies of imatinib mesylate com

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma

✍ Faye M. Johnson; Lee M. Krug; Hai T. Tran; Stephanie Shoaf; Victor G. Prieto; Ph 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 329 KB 👁 2 views

Phase II study of paclitaxel and estramu

Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma

✍ Hossein Borghaei; Michael Millenson; Russell Schilder; Mitchell Alden; Andre Rog 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 1 views

A phase II and pharmacodynamic study of

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

✍ Edwin M. Posadas; Meghan S. Liel; Virginia Kwitkowski; Lori Minasian; Andrew K. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

## Abstract ## BACKGROUND The primary objective of this study was to evaluate the biochemical effects of gefitinib on its target signal‐transduction pathways in patients with recurrent epithelial ovarian cancer (EOC). The secondary objectives included assessing clinical activity and toxicity and d

A phase 2 study of irinotecan, cisplatin

A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer

✍ Ji-Youn Han; Kun Young Lim; Sun Young Yu; Tak Yun; Heung Tae Kim; Jin Soo Lee 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 254 KB 👁 1 views

Phase 2 study of gemcitabine in combinat

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

✍ Yasuhiro Oki; Barbara Pro; Luis E. Fayad; Jorge Romaguera; Felipe Samaniego; Fre 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

## Abstract ## BACKGROUND. The management of recurrent or refractory Hodgkin lymphoma (HL) remains challenging. The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL. ## METHODS. Patients were

Phase II study of a protracted irinoteca

Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma

✍ Gianni Bisogno; Riccardo Riccardi; Antonio Ruggiero; Giampaolo Arcamone; Arcange 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

## Abstract ## BACKGROUND Irinotecan (CPT‐11) is a novel antineoplastic agent that takes effect by inhibiting topoisomerase I. The Italian Soft Tissue Sarcoma (STS) Committee performed a multiinstitutional Phase II study to evaluate its effect on STS. ## METHODS Over a 2‐year period between 2002